We have invested in manufacturing expansion for biological ECMs such as Matrigel matrix and Collagen
Since the start of the global COVID pandemic in 2020, many life sciences companies have encountered unprecedented product demand and as a result, unprecedented lead times and product delays. Corning has also experienced this for some of our most popular products such as Matrigel matrix. Once we became aware of the situation we took multiple actions to address it, including diligently working to optimize and expand manufacturing capacity across our product offerings, with a focus on critical research products such as Matrigel matrix, Collagen, and other biological ECMs. While we are working as quickly as we can to expand product availability, we have maintained our commitment to rigorous manufacturing processes and delivering the same quality product you have come to expect from Corning.